close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Amneal Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
News headline image
Amneal Reports First Quarter 2025 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal to Report First Quarter 2025 Results on May 2, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Reports Third Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal to Report Third Quarter 2024 Results on November 8, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Reports Second Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal to Report Second Quarter 2024 Results on August 9, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Releases 2023 Environmental, Social and Governance Report
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
News headline image
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.